NCT03378297View on ClinicalTrials.gov

IMPACT: A Randomized WOO Study of Novel Therapeutic Agents in Women Triaged to Primary Surgery for EOC

EARLY_PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 4, 2018

Primary Completion Date

January 5, 2023

Study Completion Date

January 5, 2023

Conditions

Ovarian Cancer

Interventions

DRUG

Metformin

Metformin tablets 850 mg x 2 orally

DRUG

Acetylsalicylic acid

Acetylsalicylic acid tablets 160 mg x1 orally

DRUG

Olaparib

Olaparib capsules 300 mg x 2 orally

DRUG

Letrozole

Letrozol tablets 2.5 mg x 1 orally

Trial Locations (2)

4068

Helse Stavanger HF, Stavanger University Hospital, Stavanger

5021

Helse Bergen HF, Haukeland University Hospital, Bergen

All Listed Sponsors

lead

Haukeland University Hospital

OTHER

NCT03378297 - IMPACT: A Randomized WOO Study of Novel Therapeutic Agents in Women Triaged to Primary Surgery for EOC | Biotech Hunter | Biotech Hunter